Exo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Tomohiro Watanabe(Ajinomoto (United States)), Yutaka Matsuda(Ajinomoto (United States)), Tatsuya Okuzumi(Suzuki (Japan)), Natsuki Shikida(Suzuki (Japan)), Kenichiro Ito(NTT Medical Center), Akira Nakayama(Shizuoka University), Yusuke Iwai(Suzuki (Japan)), Ryusuke Hirama(Suzuki (Japan)), Noriko Hatada(Suzuki (Japan)), Takuya Seki(Suzuki (Japan)), Naoko Arashida(Suzuki (Japan)), Kazutaka Shimbo(Suzuki (Japan)), Tomohiro Fujii(Suzuki (Japan))
Cited by 4
Related Papers
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296
Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease.
|Circulation|1981|250
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
|Breast Cancer Research|2009|156
Artificial human Met agonists based on macrocycle scaffolds
|Nature Communications|2015|118
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production
|Bioconjugate Chemistry|2023|62